20-F: Waldencast Reports Significant 2025 Net Loss Amidst Goodwill Impairments

Waldencast plc reported a substantial net loss of $248.1 million in 2025, primarily driven by $152.0 million in goodwill impairment charges and increased interest expenses, despite a slight revenue decrease.

Summary

• Net revenue for the year ended December 31, 2025, decreased slightly by 0.7% to $272.1 million from $273.9 million in 2024.
• The company recorded a significant net loss of $248.1 million in 2025, a substantial increase from $48.6 million in 2024.
• Operating loss widened to $217.5 million in 2025 from $58.6 million in 2024.
• Goodwill impairment charges totaled $152.0 million in 2025, affecting both Obagi Medical ($132.1 million) and Milk Makeup ($20.0 million) reporting units.
• Interest expense, net, increased by 46.3% to $25.1 million in 2025, primarily due to higher interest rates and increased debt after refinancing.
• A loss on extinguishment of debt of $24.4 million was recognized in 2025 due to comprehensive debt refinancing activities, including the termination of the JPM 2022 Credit Agreement and TCW Credit Agreement.
• The company completed the acquisition of Novaestiq Corp. in July 2025, gaining exclusive U.S. distribution rights for Saypha hyaluronic acid injectable gels, with FDA approval for Saypha MagIQ received in September 2025.
• A strategic transaction with Rohto Pharmaceutical Co., Ltd. in November 2025 involved the sale of Obagi Japan trademark rights for $82.5 million, resulting in a $5.7 million gain on sale of trademark.
• Material weaknesses in internal control over financial reporting related to control activities, monitoring, risk assessment, and delegation of authority were not fully remediated as of December 31, 2025.
• An ongoing SEC investigation related to historical accounting practices and material weaknesses continues, with the company cooperating fully.
• The Lumina Credit Agreement, entered into in November 2025 for $225.0 million, carries an initial fixed interest rate of 14.75% per annum, increasing by 0.25% quarterly after November 2026.
• The financial covenant under the Lumina Credit Agreement, requiring a maximum Total Leverage Ratio, has been suspended until December 31, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative report. The substantial net loss, significant goodwill impairments, high-interest debt, and ongoing internal control weaknesses overshadow any positive developments like the Novaestiq acquisition or trademark sale, indicating considerable financial and operational challenges.

Positives

• U.S. direct-to-consumer and U.S. retail channels experienced growth of $12.6 million and $3.9 million, respectively, in 2025.
• International Obagi distribution grew by $11.1 million year-on-year.
• FDA approval was received for Obagi Saypha MagIQ injectable hyaluronic acid gel in September 2025, expanding Obagi Medical's product offerings into aesthetic solutions.
• The sale of Obagi Japan trademark rights to Rohto Pharmaceutical Co., Ltd. generated $82.5 million in proceeds and a $5.7 million gain, with the majority used to repay debt.
• The company's cash, cash equivalents, and restricted cash increased to $31.9 million as of December 31, 2025, from $16.3 million in 2024.

Negatives

• Net loss significantly increased to $248.1 million in 2025 from $48.6 million in 2024, primarily due to non-cash charges.
• Goodwill impairment charges of $152.0 million were recorded in 2025 for both Obagi Medical and Milk Makeup reporting units, indicating discrepancies between projected and actual performance.
• International Milk Makeup net revenue fell by $19.8 million due to soft consumption and lower inventory levels held by retailers.
• Cost of goods sold increased by 8.4% to $89.1 million, partly due to inventory write-offs from a one-time product-quality matter.
• Interest expense, net, increased by 46.3% to $25.1 million, driven by higher interest rates on refinanced debt.
• A $24.4 million loss on extinguishment of debt was incurred due to debt refinancing activities.
• The company continues to have material weaknesses in internal control over financial reporting as of December 31, 2025, posing risks to financial reporting accuracy and investor confidence.
• An ongoing SEC investigation related to financial restatement and material weaknesses could lead to litigation, penalties, and reputational harm.
• The Lumina Credit Agreement includes a high initial fixed interest rate of 14.75% and significant prepayment premiums, potentially limiting future refinancing options.

Risks

• Ongoing strategic review may be costly, divert management attention, cause dilution, and fail to yield expected benefits or maximize shareholder value.
• Failure to generate sufficient cash flow from operations could hinder brand growth, force cancellation of initiatives, or necessitate additional funding on unfavorable terms.
• Unpredictable financial performance and historical net losses, with potential future declines in sales and operating results due to consumer spending fluctuations, operational challenges, and external factors.
• Failure to comply with covenants under the Lumina Credit Agreement could result in an event of default, accelerating indebtedness and materially affecting business, liquidity, and financial position.
• Ineffective inventory management could adversely affect results of operations, financial condition, and liquidity, especially with international expansion and reliance on distributor forecasts.
• Dependence on distributions from Waldencast LP to pay dividends, taxes, and other expenses, with potential restrictions on cash distributions.
• Warrants accounted for as liabilities, with changes in fair value potentially causing material fluctuations in financial results.
• Significant expenses and resource demands associated with being a publicly traded entity in an Up-C structure, disproportionately high relative to revenues.
• Potential loss of foreign private issuer status could result in significant additional cost and expense due to increased U.S. regulatory requirements.
• Failure to fully remediate material weaknesses in internal control over financial reporting could adversely affect investor confidence and business results.
• Inability to achieve full compliance with auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act by the December 31, 2026 deadline.
• Ongoing SEC investigation may result in litigation, regulatory penalties, and reputational harm.
• Conducting international business exposes the company to currency fluctuations, cash repatriation restrictions, and changes in laws and regulations.
• Product liability and other claims by consumers and third parties, with insurance potentially insufficient to cover such claims.
• Breach, termination, or dispute of intellectual property licenses could compromise commercialization of dependent products and divert resources.
• Evolving laws and regulations governing product formulation, manufacturing, testing, approval, distribution, marketing, and sale could harm the business.
• Application of the U.K. City Code on Takeovers and Mergers could impose rules and restrictions on the company.
• Volatility in the price of securities due to market factors, limited liquidity, and actions by significant shareholders.
• Failure to maintain compliance with Nasdaq continued listing standards could lead to delisting.
• Issuance of additional securities without shareholder approval could dilute ownership interests and depress market price.
• Rights and responsibilities as a shareholder are governed by Jersey law, which differs from U.S. company shareholder rights.
• Difficulty enforcing U.S. judgments against the company or its directors and officers outside the U.S.
• Terms of warrants may be amended in a manner adverse to holders with approval of 65% of outstanding public warrants.
• Company may redeem unexpired warrants prior to exercise at a disadvantageous time, making them worthless.
• Dependence on third-party logistics providers, contract manufacturers, and retailers makes the company vulnerable to disruptions, quality issues, and regulatory non-compliance.
• Intense competition in the cosmetics, skincare, and injectables industry, with challenges in product success and marketing effectiveness.
• Dependency on directors, officers, and key personnel, with risks related to attracting, retaining, and developing human capital.
• Operational complications in transport and distribution, including reliance on third-party delivery services and freight carriers.
• Failure to comply with applicable laws and regulations by the company or its CMOs could significantly harm commercial distribution.
• Obagi Medical products containing hydroquinone are marketed as prescription-use only drugs without required premarket authorization, risking removal from the market.
• Lengthy, time-consuming, and unpredictable drug regulatory approval processes for products, if required.
• Adverse events or undesirable side effects from products could lead to warnings, recalls, or regulatory enforcement.
• Failure to obtain regulatory approvals or comply with regulations in foreign jurisdictions would prevent international marketing.
• New laws, regulations, enforcement trends, or changes in existing regulations governing Milk Makeup products could harm the business.
• Potential prohibition or limitation of sale of cosmetics containing U.S. hemp and hemp-derived ingredients, including CBD, by regulatory authorities.
• Damage to reputation or brand, including through social media, or issues with product quality, efficacy, or safety, could significantly impact the business.
• Dependence on information technology systems and infrastructure, with risks of security breaches and cybersecurity threats.
• Payment methods on e-commerce websites subject the company to third-party payment processing-related risks, including fraud.
• Disparity between U.S. corporate tax rate and non-corporate member tax rate may complicate capital structure maintenance.
• Failure to comply with applicable transfer pricing and similar regulations could harm business and financial results.
• Potential treatment as a passive foreign investment company (PFIC) could result in adverse U.S. federal income tax consequences to U.S. Holders.
• Risk of being treated as a corporation resident in the U.S. for U.S. federal income tax purposes under Section 7874 of the Code.
• Tax authorities of other jurisdictions may treat the company as having a taxable presence in another jurisdiction.
• Changes in tax law could significantly affect reported earnings and cash flows, including the OECD/G20 Two Pillars Solution.

Future Outlook

The company is undertaking a strategic review to maximize shareholder value, with no assurance of specific outcomes or timelines. It plans to continue investing in brand awareness, distribution expansion, and innovation for Obagi Medical and Milk Makeup. The company anticipates increased capital and operating expenditures for international expansion and infrastructure. It expects to achieve full compliance with Sarbanes-Oxley Section 404(b) by the fiscal year ending December 31, 2026. Future profitability is uncertain due to market volatility, competition, and the need to adapt to consumer trends. The company will continue to monitor the effects of the global macroeconomic environment, including inflationary pressures.

Management Comments

• Management is actively engaged in ongoing remediation efforts to address material weaknesses in internal control over financial reporting.
• Management has concluded that the consolidated financial statements included in this Report present fairly, in all material respects, our financial position, results of operations and cash flows for the periods disclosed in conformity with GAAP, notwithstanding the identified material weaknesses.
• We believe that there is potential for significant sales growth of our products in international markets and intend to continue expanding our international presence in key locations, such as Asia, Europe and South America, through strategic relationships or expanding our own distribution structure.
• Our ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands.

Industry Context

StockSavvy.ai notes that Waldencast's performance reflects broader challenges in the beauty and wellness sector, particularly for brands navigating intense competition and rapidly shifting consumer preferences. The significant goodwill impairment charges suggest that the initial valuations of acquired brands (Obagi Medical and Milk Makeup) may have been overly optimistic or that market conditions have deteriorated more than anticipated. The strategic acquisition of Novaestiq and the Saypha HA filler line indicates a move towards diversifying Obagi Medical's offerings into the high-growth aesthetics market, a trend seen across the industry as companies seek to capture a larger share of consumer spending on advanced beauty solutions. However, this expansion also introduces new regulatory complexities and competition. The high-interest debt refinancing and ongoing internal control issues highlight operational and financial strains that could hinder the company's ability to compete effectively against larger, more financially stable conglomerates like L'Oréal, Estée Lauder, or Coty, which possess greater resources for R&D, marketing, and compliance.

Comparison to Industry Standards

• The significant goodwill impairment charges for both Obagi Medical ($132.1 million) and Milk Makeup ($20.0 million) in 2025 suggest that the company's acquired assets may have been overvalued compared to their actual performance, a common risk in M&A-heavy industries but particularly concerning given the magnitude.
• The Lumina Credit Agreement's initial fixed interest rate of 14.75% is considerably higher than typical corporate borrowing rates for established companies, indicating a higher perceived risk by lenders. For instance, larger beauty conglomerates like L'Oréal or Estée Lauder typically secure financing at much lower rates, reflecting their stronger credit profiles and market stability.
• The company's Adjusted EBITDA Margin of 5.9% in 2025 is notably lower than industry leaders. For example, L'Oréal reported an operating margin of approximately 19.5% in 2023, and Estée Lauder's operating margin was around 10.6% in its fiscal year 2023. This disparity highlights Waldencast's struggle with profitability and operational efficiency compared to global benchmarks.
• The ongoing material weaknesses in internal control over financial reporting and the SEC investigation place Waldencast significantly behind industry best practices for corporate governance and financial transparency, which can deter institutional investors who prioritize robust internal controls.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to an ongoing SEC investigation related to its proactive and voluntary self-reporting of a review of historical accounting used by Obagi Medical. A document subpoena was received in September 2023, and the company is fully cooperating.
• Management does not currently expect known legal matters to have a material adverse effect on the company's business, results of operations, liquidity, or financial condition, but acknowledges the inherent uncertainty of legal outcomes.

Related Party Transactions

• The 2023 PIPE Investment included participation from certain existing shareholders, members of the Sponsor, Michel Brousset (CEO), and Hind Sebti (CGO).
• The company has indemnification agreements with its directors and executive officers, providing indemnification against liabilities incurred in their duties.
• Obagi Medical has an Intellectual Property License Agreement and a Global Supply Services Agreement with Obagi Hong Kong Limited (owned by Cedarwalk Skincare Ltd., a major shareholder), for the sale of Obagi Medical products in the China Region. Obagi Hong Kong pays a royalty of 5.5% of gross sales.
• Milk Makeup subleases office and studio space in Los Angeles, CA, from Milk Studios Los Angeles LLC on a month-to-month basis, incurring administrative fees of $0.3 million annually.
• One of Milk Makeup's co-founders and a shareholder is party to an influencer agreement, receiving $0.1 million in fees annually for brand services.

Stakeholder Impact

• **Shareholders:** Significant net loss and goodwill impairment charges could negatively impact shareholder value. Potential dilution from warrant exercises and contingent share issuances. The ongoing strategic review aims to maximize shareholder value, but its outcome is uncertain. Foreign private issuer status means less disclosure and different shareholder rights compared to U.S. companies.
• **Employees:** The company continues to invest in people and infrastructure, but the ongoing financial challenges and strategic review could create uncertainty. Stock-based compensation is a key part of executive and employee incentives.
• **Customers:** Expansion into new product categories (HA fillers) and distribution channels aims to enhance customer offerings. However, supply chain disruptions, product quality issues, or regulatory non-compliance could negatively impact customer experience and trust.
• **Suppliers/Distributors:** Heavy reliance on third-party manufacturers and logistics providers creates vulnerability to disruptions. Changes in demand forecasts from international distributors could affect sales and inventory management.
• **Creditors:** The Lumina Credit Agreement imposes a high interest rate and prepayment premiums, indicating increased risk for creditors. The suspension of the financial covenant provides temporary relief but highlights underlying financial stress.

Next Steps

• Continue ongoing remediation efforts to address material weaknesses in internal control over financial reporting, aiming for full SOX 404(b) compliance by December 31, 2026.
• Pursue the strategic review process to identify and evaluate potential alternatives for maximizing shareholder value.
• Expand international footprint and distribution channels for Obagi Medical and Milk Makeup, investing in innovation and marketing.
• Upgrade and expand sales force and operational/regulatory compliance functions for the medical devices segment (Saypha fillers).
• Monitor and adapt to evolving regulatory requirements in international markets, particularly regarding product classifications and ingredient standards.
• Manage compliance with the financial covenant under the Lumina Credit Agreement, which commences on December 31, 2026.
• Continue cooperating with the SEC's ongoing investigation.

Key Dates

Recommendation

The company's 2025 results are significantly worse than the prior year, marked by a substantial net loss of $248.1 million and $152.0 million in goodwill impairment charges, indicating fundamental issues with asset valuation and profitability. The high-interest debt (14.75% initial fixed rate) from the Lumina Credit Agreement, coupled with ongoing material weaknesses in internal controls and an SEC investigation, points to significant financial and operational instability. While strategic acquisitions and trademark sales offer some positives, they are insufficient to offset the severe financial deterioration and heightened risks. The delay in the financial covenant commencement further underscores financial fragility. These factors collectively suggest a high-risk investment profile with significant downside potential.

Keywords

Beauty and Wellness, Skincare, Cosmetics, Obagi Medical, Milk Makeup, SEC Filing, Financial Results, Goodwill Impairment, Debt Refinancing, Lumina Credit Agreement, SEC Investigation, Internal Controls, Hyaluronic Acid Fillers, Saypha, Trademark Sale, International Expansion, E-commerce, Regulatory Compliance, Shareholder Dilution, Nasdaq Listing, Foreign Private Issuer, Risk Management, Supply Chain, Product Liability, Intellectual Property, Taxation